Back to search results

MMR Vaccine Safety and Effectiveness in Pediatric Heart Transplant Patients

This study is looking at how safe and effective the commercial measles, mumps, and rubella (MMR) vaccine is for children and teenagers (ages 1 to 17) who have had a heart transplant. Researchers want to see if the vaccine causes any side effects and if it helps these patients develop protection against measles. You might be able to join if you received a heart transplant at least one year ago and meet other specific health requirements, such as being at least one year out from certain rejection treatments. The study plans to enroll 60 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive the MMR vaccine. It is not randomized, and it aims to enroll 60 participants.
What's involved
Participants will receive the commercial MMR vaccine. Researchers will then monitor for adverse reactions for up to 240 days and check for measles protection between 60 and 240 days after vaccination.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 240 days after receiving the vaccine to check for side effects and protection against measles.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07195032

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

Recruiting
PHASE4Ages 1–17InterventionalPrevention
Children's Mercy Hospital Kansas City
~60 participants
Updated 2025-09-26 on ClinicalTrials.gov
What's tested:Commercial measles, mumps, and rubella (MMR) vaccine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants who experience adverse reactions to the measles, mumps, and rubella vaccination
Measured over Between 0-240 days after vaccine administration
+1 more outcome measured

Conditions

Heart Transplant Infection Prevention

Explore related trials

Heart Transplantation

NCT07195032

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Children's Mercy Hospital

    Kansas City, Missouristudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Victoria Blazek, PharmD, BCPPS · PRINCIPAL_INVESTIGATOR · Children's Mercy Hospital Kansas City

Who to contact

Victoria Blazek, PharmD, BCPPS
[email protected]
816-302-3724
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Received a heart transplant
At least 1 year after transplant
At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)
At least 1 year from anti-thymocyte globulin
At least 6 months after pulse dose steroid treatment or basiliximab treatment
No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion
Clinically well

Exclusion

History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.
History of anaphylactic reaction to MMR vaccination

What this trial measures

  • Number of participants who experience adverse reactions to the measles, mumps, and rubella vaccinationBetween 0-240 days after vaccine administration

    Patients will be screened for adverse reactions following vaccine administration

  • Number of participants with resultant initial seropositivity against measles after vaccinationBetween 60-240 days after vaccine administration.

    Serologic response will be measured after vaccine administration.